These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

500 related items for PubMed ID: 21883704

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.
    Rea C, Dunkerley A, Sørensen B, Rangarajan S.
    Haemophilia; 2009 Nov; 15(6):1237-42. PubMed ID: 19664015
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis--a meta-analysis.
    Gruppo RA, Brown D, Wilkes MM, Navickis RJ.
    Haemophilia; 2003 May; 9(3):251-60. PubMed ID: 12694514
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparing bleed frequency and factor concentrate use between haemophilia A and B patients.
    Nagel K, Walker I, Decker K, Chan AK, Pai MK.
    Haemophilia; 2011 Nov; 17(6):872-4. PubMed ID: 21342368
    [Abstract] [Full Text] [Related]

  • 11. Role of the B domain in proteolytic inactivation of activated coagulation factor VIII by activated protein C and activated factor X.
    Khrenov AV, Ananyeva NM, Saenko EL.
    Blood Coagul Fibrinolysis; 2006 Jul; 17(5):379-88. PubMed ID: 16788314
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials.
    Fischer K, Collins P, Björkman S, Blanchette V, Oh M, Fritsch S, Schroth P, Spotts G, Ewenstein B.
    Haemophilia; 2011 May; 17(3):433-8. PubMed ID: 21299740
    [Abstract] [Full Text] [Related]

  • 15. Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products.
    Simpson ML, Desai V, Maro GS, Yan S.
    J Manag Care Spec Pharm; 2020 Apr; 26(4):504-512. PubMed ID: 32020842
    [Abstract] [Full Text] [Related]

  • 16. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia.
    Martinowitz U, Luboshitz J, Bashari D, Ravid B, Gorina E, Regan L, Stass H, Lubetsky A.
    Haemophilia; 2009 May; 15(3):676-85. PubMed ID: 19298381
    [Abstract] [Full Text] [Related]

  • 17. Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan.
    Taki M, Shirahata A.
    Haemophilia; 2009 Jan; 15(1):78-82. PubMed ID: 18700841
    [Abstract] [Full Text] [Related]

  • 18. Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.
    Berntorp E, Negrier C, Gozzi P, Blaas PM, Lethagen S.
    Haemophilia; 2016 May; 22(3):389-96. PubMed ID: 26863900
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy.
    Abbonizio F, Giampaolo A, Coppola A, Italian Association of Haemophilia Centres, Arcieri R, Hassan HJ.
    Haemophilia; 2014 Jul; 20(4):e243-50. PubMed ID: 24834967
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.